Year Established :
1992
Main Competitive Advantages :
International Approvals/Standards,Experienced R&D Staff,Delivery Term,Large Product Line,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages :
Plasma products: Surgical Lyophilized Fibrin Sealant, Human, Human Coagulation Factor VIII, Human Albumin, Human Fibrinogen, Human Hepatitis B Immunoglobulin, Human Tetanus Immunoglobulin, Human Prothrombin Complex, Human Immunoglobulin, Human Thrombin, Lyophilized for External Use, Human Rabies Immunoglobulin, Human Immunoglobulin (pH4) for Intravenous Injection；
Vaccine products: Meningococcal Polysaccharide Vaccine Group ACYW135, Influenza Vaccine (Split Virion), Inactivated, Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Influenza A (H1N1) Vaccine, (Split, Inactivated), Influenza Vaccine(Split Virion), Inactivated，Quadrivalent, Group A and C Meningococcal Polysaccharide Vaccine;
R&D and production of monoclonal antibody products: Recombinant anti-CTL-4 human monoclonal antibody injection, Injection of Recombinant Anti-RANKL Whole Human Monoclonal Antibody Injection, Recombinant anti-Vectibix endothelial growth factor (EGFR) monoclonal antibody injection, Recombinant human anti-tumor necrosis factor (TNFα) monoclonal antibody injection, Injection-use recombinant anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, Recombinant anti-vascular endothelial growth factor (VEGF) monoclonal antibody injection, Recombinant anti-lymphoma (CD20) monoclonal antibody injection;
Shengming Bio is wholly owned subsidiary of Hualan Group and can provide CRO and CMO services related to monoclonal antibody drugs that fully meet the requirements of CFDA/FDA.
The contents of services include screening monoclonal antibody, inspection and testing, evaluation, process R&D, drug analysis, preparation development, production approval application, filling and packaging, labeling, etc.
Patents and Copyrights :
Self developed chromatography process and critical media, possesses independent intellectual property of affinity chromatography, separation and purification technology on specific immunoglobulin, ensuring high purity of extracted products and increasing the output.
Business Type :
Distributor,Trading Company,Manufacturer
R&D Capacity :
Own Brand
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Product Range :
Plasma products: Surgical Lyophilized Fibrin Sealant, Human, Human Coagulation Factor VIII, Human Albumin, Human Fibrinogen, Human Hepatitis B Immunoglobulin, Human Tetanus Immunoglobulin, Human Prothrombin Complex, Human Immunoglobulin, Human Thrombin, Lyophilized for External Use, Human Rabies Immunoglobulin, Human Immunoglobulin (pH4) for Intravenous Injection；
Vaccine products: Meningococcal Polysaccharide Vaccine Group ACYW135, Influenza Vaccine (Split Virion), Inactivated, Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Influenza A (H1N1) Vaccine, (Split, Inactivated), Influenza Vaccine(Split Virion), Inactivated，Quadrivalent, Group A and C Meningococcal Polysaccharide Vaccine;
R&D and production of monoclonal antibody products: Recombinant anti-CTL-4 human monoclonal antibody injection, Injection of Recombinant Anti-RANKL Whole Human Monoclonal Antibody Injection, Recombinant anti-Vectibix endothelial growth factor (EGFR) monoclonal antibody injection, Recombinant human anti-tumor necrosis factor (TNFα) monoclonal antibody injection, Injection-use recombinant anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, Recombinant anti-vascular endothelial growth factor (VEGF) monoclonal antibody injection, Recombinant anti-lymphoma (CD20) monoclonal antibody injection;
Shengming Bio is wholly owned subsidiary of Hualan Group and can provide CRO and CMO services related to monoclonal antibody drugs that fully meet the requirements of CFDA/FDA.
The contents of services include screening monoclonal antibody, inspection and testing, evaluation, process R&D, drug analysis, preparation development, production approval application, filling and packaging, labeling, etc.
Three years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
